PvP Biologics, born from collaboration between the University of Washington and UC Davis, has been acquired by Takeda Pharmaceutical. Their enzyme-based treatment for celiac disease, TAK-062, shows promise after successful Phase 1 trials. Originating from a student competition in 2011, PvP Biologics’ journey underscores the potential of university-industry partnerships in fostering innovation.
